Literature DB >> 8876719

A comparison of children with suprasellar germ cell tumors and craniopharyngiomas: final height, weight, endocrine, and visual sequelae after treatment.

N Ono1, H Kohga, A Zama, H K Inoue, M Tamura.   

Abstract

BACKGROUND: Although treatment results of craniopharyngiomas and germ cell tumors in children have been reported extensively, the relationship between various posttreatment sequelae and the nature of the tumor is not well understood.
METHODS: From 1968-94, 47 children with 23 suprasellar germ cell tumors and 24 craniopharyngiomas were treated at Gunma University Hospital, Japan. Forty survivors were assessed with regard to Karnofsky scores, visual scores, final height, final weight, and other endocrine sequelae as long-term functional prognostic indicators.
RESULTS: Kaplan-Meier life-table estimates and Karnofsky scores were not significantly different between the two histologic groups. The visual function of survivors did not differ significantly at diagnosis. However, the final visual function following treatment in the germ cell tumor group was better than in the craniopharyngioma group (p < 0.05). Antidiuretic hormone secretion was significantly impaired at diagnosis in the germ cell tumor group (p < 0.0001). However, there was only a marginally significant difference in posttreatment persistent diabetes insipidus. Craniopharyngioma children were shorter and more obese at diagnosis (p < 0.02), and became much more obese than germinoma children with the same hormone therapy (p < 0.003), although the height difference became insignificant following growth hormone treatment.
CONCLUSIONS: Children with craniopharyngiomas tended to have more visual disturbances, increased dwarfism and obesity, and less diabetes insipidus than patients with germ cell tumors despite adequate therapy. The method of quantifying visual function may in itself be useful.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876719     DOI: 10.1016/s0090-3019(96)00216-9

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  6 in total

1.  Functional capacity and body mass index in patients with sellar masses--cross-sectional study on 403 patients diagnosed during childhood and adolescence.

Authors:  Hermann L Müller; Ursel Gebhardt; Andreas Faldum; Angela Emser; Nicole Etavard-Gorris; Reinhard Kolb; Niels Sörensen
Journal:  Childs Nerv Syst       Date:  2005-05-12       Impact factor: 1.475

2.  Germinoma with synchronous lesions in the pineal and suprasellar regions.

Authors:  Lester Lee; Frank Saran; Darren Hargrave; István Bódi; Sanj Bassi; Tibor Hortobágyi
Journal:  Childs Nerv Syst       Date:  2006-10-13       Impact factor: 1.475

3.  Childhood craniopharyngioma in Macedonia: incidence and outcome after subtotal resection and cranial irradiation.

Authors:  Zoran S Gucev; Dragan Danilovski; Velibor Tasic; Jovica Ugrinovski; Vesna Nastova; Aleksandra Jancevska; Marina Krstevska-Konstantinova; Nada Pop-Jordanova; Ilija Kirovski
Journal:  World J Pediatr       Date:  2010-12-30       Impact factor: 2.764

4.  Rapidly growing giant suprasellar tumor in a high-risk child: treatment strategy and role of neuroendoscopic surgery in slit-like ventricles.

Authors:  Saad Hamdan Abdullah; Koreaki Irie; Shizuo Oi
Journal:  Childs Nerv Syst       Date:  2005-06-17       Impact factor: 1.475

5.  The effectiveness of interventions to treat obesity in survivors of childhood brain tumors: a systematic review protocol.

Authors:  Kuan-Wen Wang; Marlie Valencia; Laura Banfield; Ruth Chau; Adam Fleming; Sheila K Singh; Sarah Burrow; Russell J de Souza; Lehana Thabane; M Constantine Samaan
Journal:  Syst Rev       Date:  2016-06-14

6.  Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years.

Authors:  Selveta S van Santen; Daniel S Olsson; Marry M van den Heuvel-Eibrink; Mark Wijnen; Casper Hammarstrand; Joseph A M J L Janssen; Gudmundur Johansson; Aart J van der Lely; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.